Chemotherapy - Vinblastine
Brand Names: Velban, Alkaban-AQ, VLB
Vinblastine is a chemotherapy drug that is administered for the treatment of breast cancer, lung cancer, bladder cancer, and lymphoma. It functions as plant alkaloid, meaning it interferes with DNA in fast growing cells, preventing them from reproducing.
This drug is used in the treatment of both Hodgkin and Non-Hodgkin’s Lymphoma (especially Mycosis Fungoides) and is administered in conjunction with other chemotherapy drugs in the following protocols:
- ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)
- ChIVPP/EVA (chlorambucil, oncovin, procarbazine, prenisone, etoposide, vinblastine, adriamycin)
- Stanford-V (adriamycin, mustargen, bleomycin, vinblastine, oncovin, etoposide, prednisone)
Drug Administration
Vinblastine is given intravenously (IV). It is a vesicant, meaning it will irritate arteries, so it should be given through a vein only.
Side Effects
Common side effects include low blood counts, fatigue, and irritation at the injection site.
Less common side effects include hypertension (high blood pressure), myalgia (muscle pain), joint pain, diarrhea, peripheral neuropathy (numbness in the extremeties), poor appetite, nausea and vomiting, hair loss, and taste changes.
Clinical Trial Locator
Follow this link to identify a conveniently located cancer treatment center and begin the process of enrollment.
For more information on Hodgkin's Lymphoma, please see the following pages:
- Hodgkin's Disease: Chemotherapy
- Hodgkin's Lymphoma: Treatment
- Hodgkin's Lymphoma: Introduction
- Childhood Hodgkin's Disease: Chemotherapy
- Childhood Hodgkin's Lymphoma: Treatment
- Childhood Hodgkin's Lymphoma: Introduction
For more information on Non-Hodgkin's Lymphoma, please see the following pages:
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
